scholarly journals 18F-5-FPN: A Specific Probe for Monitoring Photothermal Therapy Response in Malignant Melanoma

2020 ◽  
Author(s):  
Yichun Wang ◽  
Mengting Li ◽  
Wenxia Wang ◽  
Hao Ji ◽  
Chaoyi Jia ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Pet Imaging ◽  
Fdg Pet ◽  
Photothermal Therapy ◽  
Therapy Response ◽  
Response Assessment ◽  
Response Evaluation ◽  
Pet Scanning ◽  
Significant Difference ◽  
B16f10 Tumor

Abstract Background The increasing global burden and the significant breakthroughs in malignant melanoma therapy make urgent demands on efficient response evaluation and surveillance of adverse events. Though there have been a few probes explored for early diagnosis or staging of malignant melanoma, but rare for response assessment investigations except for common 18F-deoxyglucose (18F-FDG). Thus, this research would further explore the feasibility and ability of 18F-5-fluoro-N-(2-(diethylamino)ethyl)picolinamide (18F-5-FPN)PET imaging to evaluate photothermal therapy (PTT) response of malignant melanoma, simultaneously comparing with 18F-FDG. Methods B16F10 and MDA-MB-231subcutaneous tumor models were irradiated with an 808 nm laser for PTT. 18F-5-FPN and 18F-FDG PET imaging were adopted to estimate the therapy response. B16F10, inflammatory, and MDA-MB-231 models were subjected to 18F-FDG and 18F-5-FPN PET static acquisitions and compared by quantitative data for assessing the specificity of different agents to different diseases. Furthermore, B16F10 and 231 models were exploited for survival analysis to observe the efficacy and response feature of PTT. Results Melanin in B16F10 tumors successfully transformed the optical energy into heat for PTT. H&E staining at 24 h discovered framework destruction of tumor tissue and extensive necrosis. The mean tumor uptakes of 18F-5-FPN on Day 2 (7.52 ± 3.65%ID/g) and Day 6 (10.22 ± 6.00%ID/g) were much lower than before treatment (p < 0.01). However, no significant difference of the 18F-FDG uptakes was found between Day 1 after PTT and before treatment. 18F-5-FPN PET scanning only manifested B16F10 tumor strikingly, while they all accumulated 18F-FDG highly. PTT contributed to suppressing B16F10 tumors’ growth rapidly in a short time and prolonged the median survival of B16F10 models to some extent. Whereas, both of the temperature and growth of 231 tumors were not distinctly influenced. Conclusions Compared with 18F-FDG PET scanning, 18F-5-FPN PET imaging was capable of estimating PTT efficacy in malignant melanoma, successfully monitored the occult recurrence after therapy, and distinguished malignant melanoma from inflammation and other carcinomas well by high affinity to melanin. This potential probe may provide a new approach for precise and useful response evaluation, timely therapeutic regimen management, and sensitive follow-up.

scholarly journals Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using 18F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST

2021 ◽  
Author(s):  
Kazuhiro Kitajima ◽  
Tadashi Watabe ◽  
Masatoyo Nakajo ◽  
Mana Ishibashi ◽  
Hiromitsu Daisaki ◽  
...  
Keyword(s):  
Metabolic Disease ◽  
Malignant Melanoma ◽  
Fdg Pet ◽  
Immune Checkpoint Inhibitor ◽  
Metabolic Response ◽  
Checkpoint Inhibitor ◽  
Response Evaluation ◽  
Pet Ct ◽  
Melanoma Patients ◽  
Fdg Pet Ct

Abstract Objective In malignant melanoma patients treated with immune checkpoint inhibitor (ICI) therapy, three different FDG-PET criteria, European Organization for Research and Treatment of Cancer (EORTC), PET Response Criteria in Solid Tumors (PERCIST), immunotherapy-modified PERCIST (imPERCIST), were compared regarding response evaluation and prognosis prediction using standardized uptake value (SUV) harmonization of results obtained with various PET/CT scanners installed at different centers. Materials and methods Malignant melanoma patients (n = 27) underwent FDG-PET/CT examinations before and again 3 to 9 months after therapy initiation (nivolumab, n = 21; pembrolizumab, n = 6) with different PET scanners at five hospitals. EORTC, PERCIST, and imPERCIST criteria were used to evaluate therapeutic response, then concordance of the results was assessed using Cohen’s κ coefficient. Log-rank and Cox methods were employed to determine progression-free (PFS) and overall (OS) survival. Results Complete metabolic response (CMR)/partial metabolic response (PMR)/stable metabolic disease (SMD)/progressive metabolic disease (PMD) with harmonized EORTC, PERCIST, and imPERCIST was seen in 3/5/4/15, 4/5/3/15, and 4/5/5/13 patients, respectively. Nearly perfect concordance between each pair of criteria was noted (κ = 0.939–0.972). Twenty patients showed progression and 14 died from malignant melanoma after a median 19.2 months. Responders (CMR/PMR) showed significantly longer PFS and OS than non-responders (SMD/PMD) (harmonized EORTC: p < 0.0001 and p = 0.011; harmonized PERCIST: p < 0.0001 and p = 0.0012; harmonized imPERCIST: p < 0.0001 and p = 0.0012, respectively). Conclusions All harmonized FDG-PET criteria (EORTC, PERCIST, imPERCIST) showed accuracy for response evaluation of ICI therapy and prediction of malignant melanoma patient prognosis. Additional studies to determine their value in larger study populations will be necessary.

Solitary Splenic Metastasis in a Patient With a Malignant Melanoma Diagnosed With F-18-FDG PET Scanning

2005 ◽  
Vol 30 (8) ◽  
pp. 582-583 ◽  
Author(s):  
Henriette M. E. Quarles van Ufford ◽  
Peter J. C. Zoon ◽  
Paul F. G. M. van Waes ◽  
Gerard van Herk ◽  
John M. H. de Klerk
Keyword(s):  
Malignant Melanoma ◽  
Fdg Pet ◽  
Splenic Metastasis ◽  
Pet Scanning

scholarly journals 18F-FDG PET/MRI for Therapy Response Assessment of Isolated Limb Perfusion in Patients with Soft-Tissue Sarcomas

2019 ◽  
Vol 60 (11) ◽  
pp. 1537-1542 ◽  
Author(s):  
Johannes Grueneisen ◽  
Benedikt Schaarschmidt ◽  
Aydin Demircioglu ◽  
Michal Chodyla ◽  
Ole Martin ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Fdg Pet ◽  
Soft Tissue Sarcomas ◽  
Therapy Response ◽  
Response Assessment ◽  
Isolated Limb Perfusion ◽  
Limb Perfusion ◽  
Therapy Response Assessment ◽  
18F Fdg

Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1460-1460
Author(s):  
Lale Kostakoglu ◽  
David J. Straus ◽  
Heiko Schöder ◽  
Ann S. LaCasce ◽  
Nancy L Bartlett ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Fdg Pet ◽  
Early Stage ◽  
International Workshop ◽  
Response Evaluation ◽  
Treatment Change ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Early Results ◽  
Pet Ct

Abstract Clinical trials are underway using FDG PET imaging as a response surrogate for risk-adapted treatments to achieve favorable long term outcome while reducing therapy-related toxicities in patients with HL. The IHP provided “guidelines” to standardize FDG PET-based response evaluation. Before implementation in clinical practice, further validation of these guidelines is necessary. Our objective was to validate IHP criteria for response evaluation after 2 cycles of therapy with prospectively collected data in CALGB 50203, a trial of AVG for the initial treatment of stages I and II non-bulky HL. IHP-based PET interpretation was also compared with CT-based lesion size changes. Methods: Treatment consisted of doxorubicin 25 mg/m2, vinblastine 6 mg/m2 and gemcitabine 800mg/m2 every 2 weeks for 12 treatments (6 cycles). Responses were assessed according to the International Workshop criteria (JCO1999:17: 1244–53). FDG-PET imaging (PET/CT: 60 pts, PET alone: 15 pts) and a separate dedicated diagnostic CT scan of involved sites was performed at baseline and after two cycles of AVG (PET-2). No treatment change was allowed on the basis of the PET-2 results. Of 99 assessable patients, 75 had PET-alone (14) or PET/CT (61) after 2 cycles; median age:34 yrs (18–80), 32% were ≥45 yrs, stages: 78% IA-IIA, 22% IIB. The primary interpretation of PET-2 studies was based on IHP criteria (JCO2007;25:571). The % change in the sum of the products of the diameter (%SPD) of all measurable lesions were compared between baseline and at cycle-2 CT. PET-2 and cycle-2 CT data were correlated with progression free survival (PFS). Results: Fifty-six patients (75%) achieved a CR/CRu, 21% a partial response (PR), 4% had stable disease (SD). After a median follow up of 2.1 yrs (1.2–3.4 years), 19 of 75 patients relapsed/progressed, with an estimated 2-year PFS of 0.87 (95% CI [0.74,0.94]Only 10 of 56 patients (18%) with CR/CRu were PET positive at PET-2 compared to 13/19 (68%) of those with SD or PR (p&lt;0.0001). Twelve of 23 (52%) PET-2 positive patients relapsed compared to 7 of 52 (13.5%) who were PET-2 negative. The 2-yr probability of PFS was 0.87, [95% CI (0.74,0.94)] among PET-2 negative patients vs. 0.47 [95% CI (0.26,0.66)] in those who were PET-2 positive, p=0.0001. In an exclusive analysis of PET/CT scans, the 2-yr probability of PFS was 0.90, [95% CI (0.75,0.96)] among PET-2 negative patients vs. 0.35 [95% CI (0.13,0.59)] in those who were PET-2 positive, p&lt;0.0001. The best PFS cut-point for %SPD change at cycle-2 was 70%. After cycle-2, PET-negative patients had a higher %SPD change compared to PET-positive patients (74.5% vs. 64.5%, p=0.003). Adjusted for baseline SPD, patients with &lt;70% change were at 5.3 times higher risk of relapse. The 2-yr probability of PFS was 0.89, [95% CI (0.73,0.95)] among patients with &gt; 70% change vs. 0.55 [95% CI (0.36,0.71)] in those with &lt; 70% change, p=0.003. Conclusion: IHP-based interpretation of FDG PET after 2 cycles of chemotherapy yields a high correlation with 2-year PFS, in particular for combined PET/CT, thus, it could be used as a response surrogate for risk-adapted treatments. The prediction of PFS using FDG-PET is superior to %SPD change after 2 cycles of therapy. Ongoing studies will prospectively define the role of interim FDG PET in tailoring treatment to optimize benefits and minimize risks.

scholarly journals Therapy Response Evaluation With Fdg-Pet/Ct In Thoracic Malignancies

2015 ◽  
Vol 6 (2) ◽  
pp. 207-216
Author(s):  
Zeynep Gozde Ozkan ◽  
Cuneyt Turkmen
Keyword(s):  
Fdg Pet ◽  
Therapy Response ◽  
Response Evaluation ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Thoracic Malignancies

scholarly journals Therapy Response Assessment of Pediatric Tumors with Whole-Body Diffusion-weighted MRI and FDG PET/MRI

Radiology ◽  
2020 ◽  
Vol 296 (1) ◽  
pp. 143-151
Author(s):  
Ashok J. Theruvath ◽  
Florian Siedek ◽  
Anne M. Muehe ◽  
Jordi Garcia-Diaz ◽  
Julian Kirchner ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Therapy Response ◽  
Response Assessment ◽  
Whole Body ◽  
Pediatric Tumors ◽  
Diffusion Weighted Mri ◽  
Diffusion Weighted ◽  
Therapy Response Assessment

Early cancer therapy response assessment by quantitative F-18 FDG PET/CT

2010 ◽  
Author(s):  
James M. Mountz ◽  
Charles Laymon ◽  
Erin Deeb ◽  
Yin Jie Chen
Keyword(s):  
Cancer Therapy ◽  
Fdg Pet ◽  
Early Cancer ◽  
Therapy Response ◽  
Response Assessment ◽  
Pet Ct ◽  
Therapy Response Assessment ◽  
Fdg Pet Ct

Marked Improvement in Detecting the Number of Involved Nodal Areas in Lymphoma, Using 18 F- FDG - PET and CT Scan.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1344-1344
Author(s):  
Juan Chalapud ◽  
Pedro Sobrevilla-Calvo ◽  
Silvia Rivas-Vera ◽  
Javier Altamirano-Levy
Keyword(s):  
Pet Imaging ◽  
Fdg Pet ◽  
Hodgkin’S Lymphoma ◽  
Cell Lymphoma ◽  
International Prognostic Index ◽  
Tertiary Care ◽  
Prognostic Index ◽  
Hodgkin's Lymphoma ◽  
Pet Scanning ◽  
Pet Ct

Abstract Positron emission tomography (PET) imaging with 18-fluoro-2-deoxiglucose (FDG) is used increasingly for the initial evaluation and staging of patients with Hodgkin’s lymphoma (HL) and non- Hodgkin’s lymphoma (NHL). However, the degree of concordance of PET and TAC scanning for each nodal and extra nodal site are not well defined. The number of nodal areas involved is a new prognostic factor in follicular lymphomas as was demonstrated in the Follicular Lymphoma (FL) International prognostic index (FLIPI), and their use may be useful for the LNH and HL. In this study, we examined the performance of CT versus FDG-PET scanning, comparing each one of the nodal and extra nodal areas, as it is described in the FLIPI, in a retrospective cohort of lymphoma patients (pts) with HL and NHL. We reviewed the charts of 56 patients with diagnosis of HL and NHL in the initial and relapse staging, in a single tertiary care center. All patients had FDG-PET imaging study, clinical examination and CT scans. The Ann Arbor stage, each nodal site (cervical, mediastinal, axillary, mesenteric, para aortic, inguinal), and extra nodal sites were evaluated on the basis of FDG-PET scanning and were compared with the findings derived from CT. Bone marrow biopsy results were excluded from this initial analysis. The histopathological diagnoses included diffuse large B-cell Lymphomas in 20/56 pts (36%), HL 15/56 pts (27%), anaplastic large cell lymphoma 8/56 pts (14%), FL 5/56 pts (9%), peripheral T-cell Lymphoma 4/56 (7%) and others 7%. Among the 56 pts, 22 (39%) had discordant results between FDG-PET scanning and CT scanning, that lead to a change in stage assignment. Among the discordant cases FDG-PET resulted in upstaging in 18/56 pts (32%), and down staging in 4/56 pts (7%). Forty for pts (79%) had discordant results in the number of nodal areas, among the discordant cases FDG-PET detected more nodal areas in 36/56 pts (64%) and CT in 8/56 pts (14%). The discordant cases were distributed as it is shown in the table. In conclusion Pet and CT in combination detects more involved nodal areas than each method by itself. Summary of PET/CT correlation with nodal areas Nodal areas Cervical(n) Axillar (n) Mediastinal(n) Paraaortic(n) Inguinal (n) positive total 40 26 26 24 17 Only Positive FDG-PET 16 12 13 7 11 Only Positive CT 7 3 2 2 1 Positive FGD-PET + CT 17 11 11 15 5

scholarly journals Maximum Standardized Uptake Value of 18F-deoxyglucose PET Imaging Increases the Effectiveness of CT Radiomics in Differentiating Benign and Malignant Pulmonary Ground-Glass Nodules

2021 ◽  
Vol 11 ◽  
Author(s):  
Rong Niu ◽  
Jianxiong Gao ◽  
Xiaoliang Shao ◽  
Jianfeng Wang ◽  
Zhenxing Jiang ◽  
...  
Keyword(s):  
Pet Imaging ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Ground Glass ◽  
Semantic Features ◽  
Diagnostic Efficiency ◽  
Maximum Standardized Uptake Value ◽  
Pet Ct ◽  
Significant Difference ◽  
Ground Glass Nodules

To investigate whether the maximum standardized uptake value (SUVmax) of 18F-deoxyglucose (FDG) PET imaging can increase the diagnostic efficiency of CT radiomics-based prediction model in differentiating benign and malignant pulmonary ground-glass nodules (GGNs). We retrospectively collected 190 GGNs from 165 patients who underwent 18F-FDG PET/CT examination from January 2012 to March 2020. Propensity score matching (PSM) was performed to select GGNs with similar baseline characteristics. LIFEx software was used to extract 49 CT radiomic features, and the least absolute shrinkage and selection operator (LASSO) algorithm was used to select parameters and establish the Rad-score. Logistic regression analysis was performed combined with semantic features to construct a CT radiomics model, which was combined with SUVmax to establish the PET + CT radiomics model. Receiver operating characteristic (ROC) was used to compare the diagnostic efficacy of different models. After PSM at 1:4, 190 GGNs were divided into benign group (n = 23) and adenocarcinoma group (n = 92). After texture analysis, the Rad-score with three CT texture features was constructed for each nodule. Compared with the Rad-score and CT radiomics model (AUC: 0.704 (95%CI: 0.562-0.845) and 0.908 (95%CI: 0.842-0.975), respectively), PET + CT radiomics model had the best diagnostic efficiency (AUC: 0.940, 95%CI: 0.889-0.990), and there was significant difference between each two of them (P = 0.001-0.030). SUVmax can effectively improve CT radiomics model performance in the differential diagnosis of benign and malignant GGNs. PET + CT radiomics might become a noninvasive and reliable method for differentiating of GGNs.

Sign in / Sign up

Export Citation Format

Share Document